Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06159790
Other study ID # CGME751A12301
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date April 29, 2024
Est. completion date August 28, 2026

Study information

Verified date March 2024
Source Sandoz
Contact Clinical Disclosure Representative
Phone +49 8024 / 908 0
Email sandoz.disclosure@sandoz.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the efficacy, safety, and immunogenicity of GME751 compared with Keytruda® (pembrolizumab) in participants with untreated metastatic non-squamous NSCLC (irrespective of PD-L1 status), without sensitizing EGFR or ALK mutations.


Description:

Eligible participants will be randomized in a 1:1 ratio to receive either GME751, or European Union (EU)-authorized pembrolizumab (Keytruda-EU) in combination with chemotherapy. The maximum study duration for a participant will be approximately 56 weeks including screening. Treatment duration is 52 weeks (17 treatment cycles of study treatment GME751 or Keytruda-EU in combination with chemotherapy, each cycle with a duration of 3 weeks). Participants will discontinue study participation in case of disease progression, unacceptable toxicity or other reasons. Participants who are benefiting from treatment with pembrolizumab without signs of progression or unacceptable toxicity will be eligible for continued pembrolizumab treatment via most suitable option based on the respective country regulations.


Recruitment information / eligibility

Status Recruiting
Enrollment 720
Est. completion date August 28, 2026
Est. primary completion date August 28, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - At least 18 years of age - Untreated metastatic NSCLC - Absence of tumor activating EGFR mutations and absence of ALK gene rearrangements - Measurable disease according to RECIST 1.1 - Adequate organ function - Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 Exclusion Criteria: - Squamous cell or mixed histology in NSCLC - Known history of hypersensitivity (grade =3) to pembrolizumab, chemotherapy or their excipients - Active autoimmune disease that has required chronic systemic treatment in the past 2 years. - Received live vaccine =30 days before the first study treatment - Prior treatment with pembrolizumab or any other anti-PD-1, or anti-PD-L1 or anti-PD-L2, or anti-CTLA-4 agent or any antibody targeting other immune-regulatory receptors or mechanisms for lung cancer. Other protocol-defined inclusion/exclusion criteria apply.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
GME751
Drug: GME751 Concentrate for solution for infusion, Biologic, Liquid in vial, 100 mg, 200 mg every 3 weeks, i.v. infusion Drug: Pemetrexed (i.v. infusion) Drug: Carboplatin or Cisplatin (i.v. infusion)
Keytruda-EU
Drug: Keytruda-EU Concentrate for solution for infusion, biologic, liquid in vial, 100 mg, 200mg every 3 weeks, i.v. infusion Drug: Pemetrexed (i.v. infusion) Drug: Carboplatin or Cisplatin (i.v. infusion)

Locations

Country Name City State
Georgia Sandoz Investigational Site Tbilisi

Sponsors (1)

Lead Sponsor Collaborator
Sandoz

Country where clinical trial is conducted

Georgia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Best Overall Response (BOR) Best Overall Response (BOR) of either Complete Response (CR) or Partial Response (PR) up to 9 months according to RECIST 1.1 as assessed by Blinded Central Imaging up to 9 months from date of randomization
See also
  Status Clinical Trial Phase
Completed NCT01438307 - Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer Phase 2
Recruiting NCT05091190 - Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers N/A
Recruiting NCT04170634 - Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study
Recruiting NCT05339568 - Patient's Whole Process Follow-up Management(HOPE-1)
Recruiting NCT05255302 - De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction Phase 2/Phase 3
Withdrawn NCT04615884 - Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients N/A
Recruiting NCT04846452 - Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC Phase 2
Recruiting NCT05480865 - SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation Phase 1
Terminated NCT03417882 - GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC Phase 2
Recruiting NCT03589339 - NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy Phase 1
Suspended NCT05617313 - Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer Phase 2
Recruiting NCT05403385 - Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer Phase 2